russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2024-5689NGLELHrussjcardiol-5689Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯ. ОБЗОР ЛИТЕРАТУРЫCLINIC AND PHARMACOTHERAPY. LITERATURE REVIEWСовременные стратегии терапии СД 2 у пациентов со стабильной ишемической болезнью сердца. Старые цели, новые возможности (обзор литературы)Modern strategies for the treatment of type 2 diabetes in patients with stable coronary artery disease. Old goals, new opportunities (literature review)https://orcid.org/0000-0002-4830-5220ГришаевС. Л.GrishaevS. L.

д. м. н., профессор, профессор кафедры военно-морской терапии

Санкт-Петербург

Professor of the Department of Naval Therapy, Professor, MD

St. Petersburg

grishaev_med@mail.ruhttps://orcid.org/0000-0003-1363-6860ЧеркашинД. В.CherkashinD. V.

д. м. н., профессор, начальник кафедры военно-морской терапии

Санкт-Петербург

Head of the Department of Naval Therapy, Professor, MD

St. Petersburg

cherkashin_dmitr@mail.ruhttps://orcid.org/0000-0003-1851-0941СалуховВ. В.SalukhovV. V.

д. м. н., профессор, начальник 1 кафедры (терапии усовершенствования врачей)

Санкт-Петербург

Head of the 1st Department (Advanced Medical training therapy), Professor, MD

St. Petersburg

vlasaluk@yandex.ruhttps://orcid.org/0000-0002-4135-5815АланичевА. Е.AlanichevA. E.

к. м. н., доцент кафедры военно-морской терапии

Санкт-Петербург

Associate Professor of the Department of Naval Therapy, PhD

St. Petersburg

alanichevae80@mail.ruФГБВОУ ВО Военно-медицинская академия им. С. М. Кирова МО РФРоссияKirov Military Medical AcademyRussian FederationФГБВОУ ВО Военно-медицинская академия им. С. М. Кирова МО РФРоссияMilitary Medical Academy n.a. S.M. KirovRussian Federation20241501202429256895689Copyright © Гришаев С.Л., Черкашин Д.В., Салухов В.В., Аланичев А.Е., 20242024Гришаев С.Л., Черкашин Д.В., Салухов В.В., Аланичев А.Е.Grishaev S.L., Cherkashin D.V., Salukhov V.V., Alanichev A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5689

В обзоре суммированы и проанализированы имеющиеся литературные данные с целью предоставления информации врачам о лучших стратегиях лечения сахарного диабета 2 типа при стабильной ишемической болезни сердца. Содержащаяся в обзоре информация должна помочь в принятии решений специалистами сферы здравоохранения в рутинной клинической практике. Рекомендации Европейского общества кардиологов 2023г, алгоритмы специализированной медицинской помощи больным сахарным диабетом Минздрава России 2023г предлагают отдавать предпочтение сахароснижающим препаратам с доказанной пользой для сердечно-сосудистой системы, за которыми следуют препараты с доказанной безопасностью для сердечно-сосудистой системы.

The review summarizes and analyzes the available literature to provide information to clinicians about the best treatment strategies for type 2 diabetes in stable coronary artery disease. This data should help health care professionals make decisions in routine practice. 2023 European and Russian guidelines on type 2 diabetes suggest giving preference to glucose-lowering agents with proven benefits for the cardiovascular system, followed by drugs with proven safety for the cardiovascular system.

рекомендациисахарный диабетстабильная ишемическая болезнь сердцаоценка сердечно-сосудистого рискаантагонисты рецепторов глюкагоноподобного пептида-1ингибиторы натрий-глюкозного котранспортера 2-го типа.guidelinesdiabetesstable coronary artery diseasecardiovascular risk assessmentglucagon-like peptide-1 receptor antagonistssodium-glucose cotransporter 2 inhibitorsReferencesРоссийское кардиологическое общество (РКО). Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076.Russian Society of Cardiology (RSC) 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560-4071-2020-4076.Дедов И. И., Шестакова М. В., Викулова О. К. и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010-2022 гг. Сахарный диабет. 2023;26(2):104-23. doi:10.14341/DM13035.Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010-2022. Diabetes mellitus. 2023;26(2):104-23. (In Russ.) doi:10.14341/DM13035.Дедов И. И., Шестакова М. В., Галстян Г. Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12. doi:10.14341/DM2004116-17.Dedov II, Shestakova MV, Galstyan GR. Prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104-12. (In Russ.) doi:10.14341/DM2004116-17.Сергиенко И. В., Аншелес А. А., Халимов Ю. Ш. и др. Кардиологические аспекты сахарного диабета 2 типа. Москва: Издательство "Перо". 2018. с. 68. ISBN: 978-5-00122-645-1.Sergienko IV, Ansheles AA, Khalimov YuSh, et al. Cardiological aspects of type 2 diabetes mellitus. Moscow: Izdatel'stvo "Pero". 2018. p. 68. (In Russ.) ISBN: 978-5-00122-645-1.Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnoses and management of chronic coronary syndroms. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnoses and management of chronic coronary syndroms. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(39):4043-140. doi:10.1093/eurheartj/ehad192.Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(39):4043-140. doi:10.1093/eurheartj/ehad192.Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798-813. doi:10.1161/CIRCULATIONAHA.109.913376.Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798-813. doi:10.1161/CIRCULATIONAHA.109.913376.Аметов А. С., Пьяных О. П., Голодников И. И. Избранные лекции XVIII Всемирного конгресса по инсулинорезистентности "Диабет и сердечно-сосудистые заболевания". Эндокринология: новости, мнения, обучение. 2021;10(1):8-13. doi:10.33029/2304-9529-2021-10-1-8-13.Ametov AS, Pyanykh OP, Golodnikov II. Selected lectures of the XVIII World Congress on Insulin Resistance "Diabetes and cardiovascular diseases". Endocrinology: news, opinions, training. 2021;10(1):8-13. (In Russ.) doi:10.33029/2304-9529-2021-10-1-8-13.Rocca B, Patrono C. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a new perspective. Diabetes Res Clin Practice. 2020;160:108008. doi:10.1016/j.diabres.2020.108008.Rocca B, Patrono C. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a new perspective. Diabetes Res Clin Practice. 2020;160:108008. doi:10.1016/j.diabres.2020.108008.ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overiew of individual data from 100,000 patients in randomized trials. Circulation. 1998;97(22):2202-12. doi:10.1161/01.cir.97.22.2202.ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overiew of individual data from 100,000 patients in randomized trials. Circulation. 1998;97(22):2202-12. doi:10.1161/01.cir.97.22.2202.Перепеч Н. Б. Симптоматическая фармакотерапия стабильной ишемической болезни сердца: принципы точной настройки. Consilium Medicum. 2018;20(12):8-14. doi:10.26442/20751753.2018.12.000052.Perepech NB. Symptomatic pharmacotherapy of stable coronary heart disease: principles of fine tuning. Consilium Medicum. 2018;20(12):8-14. (In Russ.) doi:10.26442/20751753.2018.12.000052.Ferrari R, Camici PG, Crea F, et al. Expert consensus document: a "diamond" approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120-32. doi:10.1038/nrcardio.2017.131.Ferrari R, Camici PG, Crea F, et al. Expert consensus document: a "diamond" approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120-32. doi:10.1038/nrcardio.2017.131.American Diabetes Association. Standards of Medical Care in Diabetes — 2021 Abridged for Primary Care Providers. Clin Diabetes 2021;39(1):14-43. doi:10.2337/cd21-as01.American Diabetes Association. Standards of Medical Care in Diabetes — 2021 Abridged for Primary Care Providers. Clin Diabetes 2021;39(1):14-43. doi:10.2337/cd21-as01.Dasgupta A, Steinhubl SR, Bhatt DL, et al. CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance CHARISMA trial). Am J Cardiol. 2009;103:1359-63. doi:10.1016/j.amjcard.2009.01.342.Dasgupta A, Steinhubl SR, Bhatt DL, et al. CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance CHARISMA trial). Am J Cardiol. 2009;103:1359-63. doi:10.1016/j.amjcard.2009.01.342.Connolly SJ, Eikelboom JW, Bosch J, et al. COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an inter-national, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:205-18. doi:10.1016/S0140-6736(17)32458-3.Connolly SJ, Eikelboom JW, Bosch J, et al. COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an inter-national, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:205-18. doi:10.1016/S0140-6736(17)32458-3.Crandall JP, Mather K, Rajpathak SN, et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care. 2017; 5:e000438. doi:10.1136/bmjdrc-2017-000438.Crandall JP, Mather K, Rajpathak SN, et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care. 2017; 5:e000438. doi:10.1136/bmjdrc-2017-000438.Tsujimoto T, Kajio H, Shapiro MF, et al. Risk of all-cause mortality in diabetic patients taking beta-blockers. Mayo Clin Proc. 2018;93:409-18. doi:10.1016/j.mayocp.2017.11.019.Tsujimoto T, Kajio H, Shapiro MF, et al. Risk of all-cause mortality in diabetic patients taking beta-blockers. Mayo Clin Proc. 2018;93:409-18. doi:10.1016/j.mayocp.2017.11.019.Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012;97(1):41-8. doi:10.1210/jc.2011-1679.Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012;97(1):41-8. doi:10.1210/jc.2011-1679.Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(7):1617-35. doi:10.2337/dci20-0022.Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(7):1617-35. doi:10.2337/dci20-0022.American Diabetes Association. Standards of Medical Care in Diabetes — 2022. Diabetes Care. 2022;45(Suppl. 1):S1-S2. doi:10.2337/dc22-Sint.American Diabetes Association. Standards of Medical Care in Diabetes — 2022. Diabetes Care. 2022;45(Suppl. 1):S1-S2. doi:10.2337/dc22-Sint.Fitchett D, Zinman B, Wanner C, et al. EMPA-REG OUTCOME trial investiga-tors. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37:1526-34. doi:10.1093/eurheartj/ehv728.Fitchett D, Zinman B, Wanner C, et al. EMPA-REG OUTCOME trial investiga-tors. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37:1526-34. doi:10.1093/eurheartj/ehv728.Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program collaborative group. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab. 2017;19(7):926-35. doi:10.1111/dom.12924.Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program collaborative group. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab. 2017;19(7):926-35. doi:10.1111/dom.12924.Wiviott SD, Raz I, Bonaca MP, et al. DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. doi:10.1056/NEJMoa1812389.Wiviott SD, Raz I, Bonaca MP, et al. DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. doi:10.1056/NEJMoa1812389.Cosentino F, Cannon Ch, Cherney DZ, et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205-15. doi:10.1161/CIRCULATIONAHA.120.050255.Cosentino F, Cannon Ch, Cherney DZ, et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205-15. doi:10.1161/CIRCULATIONAHA.120.050255.Szarek M, Bhatt DL, Steg PhG, et al. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized SOLOIST-WHF Trial. Ann Intern Med. 2021;174(8):1065-72. doi:10.7326/M21-0651.Szarek M, Bhatt DL, Steg PhG, et al. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized SOLOIST-WHF Trial. Ann Intern Med. 2021;174(8):1065-72. doi:10.7326/M21-0651.Muskiet MH, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859-69. doi:10.1016/S2213-8587(18)30268-7.Muskiet MH, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859-69. doi:10.1016/S2213-8587(18)30268-7.Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823-30.e5. doi:10.1016/j.ahj.2013.07.012.Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823-30.e5. doi:10.1016/j.ahj.2013.07.012.Leiter LA, Bain SC, Hramiak I, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18:73. doi:10.1186/s12933-019-0871-8.Leiter LA, Bain SC, Hramiak I, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18:73. doi:10.1186/s12933-019-0871-8.Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30. doi:10.1016/S0140-6736(19)31149-3.Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30. doi:10.1016/S0140-6736(19)31149-3.Green JB, Hernandez AF, D'Agostino RB, et al. HARMONY Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. Am Heart J. 2018;203:30-8. doi:10.1016/j.ahj.2018.03.030.Green JB, Hernandez AF, D'Agostino RB, et al. HARMONY Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. Am Heart J. 2018;203:30-8. doi:10.1016/j.ahj.2018.03.030.Sattar N, Lee MM, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653-62. doi:10.1016/S2213-8587(21)00203-5.Sattar N, Lee MM, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653-62. doi:10.1016/S2213-8587(21)00203-5.Verdecchia P, Murdolo G, Coiro S, et al. Therapy of Type 2 diabetes: more gliflozines and less metformin? Eur Heart J Suppl. 2023;25(Suppl.B):B171-B176. doi:10.1093/eurheartjsupp/suad098.Verdecchia P, Murdolo G, Coiro S, et al. Therapy of Type 2 diabetes: more gliflozines and less metformin? Eur Heart J Suppl. 2023;25(Suppl.B):B171-B176. doi:10.1093/eurheartjsupp/suad098.Adler AL. UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes. Diabet Med. 2008;2:41-6. doi:10.1111/j.1464-5491.2008.02498.x.Adler AL. UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes. Diabet Med. 2008;2:41-6. doi:10.1111/j.1464-5491.2008.02498.x.Rosenstock J, Kahn SE, Johansen OE, et al. The CAROLINA investigators: Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155-66. doi:10.1001/jama.2019.13772.Rosenstock J, Kahn SE, Johansen OE, et al. The CAROLINA investigators: Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155-66. doi:10.1001/jama.2019.13772.Holman RR, Coleman RL, Chan JCN, et al. ACE Study Group. Effects of acarbose on cardiovascular and diabetes out-comes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):877-86. doi:10.1016/S2213-8587(17)30309-1.Holman RR, Coleman RL, Chan JCN, et al. ACE Study Group. Effects of acarbose on cardiovascular and diabetes out-comes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):877-86. doi:10.1016/S2213-8587(17)30309-1.Салухов В. В., Ковалевская Е. А. Переосмысление роли пиоглитазона в современной диабетологии с позиции его кардиоренопротективных свойств. Медицинский совет. 2022;16(10):10-21. doi:10.21518/2079-701X-2022-16-10-10-21.Salukhov VV, Kovalevskaya EA. Rethinking the role of pioglitazone in modern diabetology from the perspective of its cardiorenoprotective properties. Medical advice. 2022;16(10):10-21. (In Russ.) doi:10.21518/2079-701X-2022-16-10-10-21.Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-97. doi:10.1016/S2213-8587(17)30317-0.Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-97. doi:10.1016/S2213-8587(17)30317-0.Zhou Yu, Huang Ya, Ji Xi, et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab. 2020;105(5):dgz252. doi:10.1210/clinem/dgz252.Zhou Yu, Huang Ya, Ji Xi, et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab. 2020;105(5):dgz252. doi:10.1210/clinem/dgz252.Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17(1):39. doi:10.1186/s12933-018-0682-3.Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17(1):39. doi:10.1186/s12933-018-0682-3.

The authors declare that there are no conflicts of interest present.